Wells Fargo’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.38M Sell
42,279
-48,839
-54% -$3.18M ﹤0.01% 3134
2025
Q4
$7.3M Buy
91,118
+39,270
+76% +$2.64M ﹤0.01% 2323
2025
Q3
$2.53M Buy
51,848
+4,775
+10% +$296K ﹤0.01% 3154
2025
Q2
$3.51M Buy
47,073
+18,868
+67% +$1.25M ﹤0.01% 2739
2025
Q1
$1.79M Sell
28,205
-9,678
-26% -$658K ﹤0.01% 3247
2024
Q4
$2.96M Sell
37,883
-17,161
-31% -$1.38M ﹤0.01% 2874
2024
Q3
$4.42M Sell
55,044
-2,214
-4% -$179K ﹤0.01% 2436
2024
Q2
$4.74M Buy
57,258
+25,129
+78% +$2.21M ﹤0.01% 2294
2024
Q1
$2.74M Buy
32,129
+240
+0.8% +$18.8K ﹤0.01% 2729
2023
Q4
$2.73M Buy
31,889
+957
+3% +$82.7K ﹤0.01% 2658
2023
Q3
$2.77M Sell
30,932
-9,875
-24% -$882K ﹤0.01% 2546
2023
Q2
$3.47M Buy
40,807
+13,507
+49% +$1.14M ﹤0.01% 2444
2023
Q1
$2.26M Buy
27,300
+13,255
+94% +$1.07M ﹤0.01% 2763
2022
Q4
$1.1M Sell
14,045
-1,838
-12% -$148K ﹤0.01% 3188
2022
Q3
$1.18M Buy
15,883
+2,663
+20% +$191K ﹤0.01% 3129
2022
Q2
$862K Sell
13,220
-49,887
-79% -$2.95M ﹤0.01% 3384
2022
Q1
$3.99M Sell
63,107
-2,723
-4% -$148K ﹤0.01% 2650
2021
Q4
$3.49M Sell
65,830
-309,991
-82% -$18.9M ﹤0.01% 2928
2021
Q3
$26.5M Sell
375,821
-126,508
-25% -$7.98M 0.01% 1444
2021
Q2
$33.5M Sell
502,329
-48,243
-9% -$3.41M 0.01% 1325
2021
Q1
$61.1M Sell
550,572
-665,468
-55% -$82.3M 0.01% 942
2020
Q4
$144M Buy
1,216,040
+180,109
+17% +$19.4M 0.03% 488
2020
Q3
$90.4M Buy
1,035,931
+171,266
+20% +$15M 0.03% 606
2020
Q2
$77.4M Buy
864,665
+86,522
+11% +$8.74M 0.02% 654
2020
Q1
$77.5M Buy
778,143
+69,730
+10% +$7.56M 0.03% 560
2019
Q4
$81.4M Sell
708,413
-210,126
-23% -$25.4M 0.02% 688
2019
Q3
$116M Sell
918,539
-206,728
-18% -$26.2M 0.03% 511
2019
Q2
$135M Buy
1,125,267
+165,586
+17% +$16.3M 0.04% 454
2019
Q1
$84M Buy
959,681
+62,238
+7% +$5.66M 0.03% 626
2018
Q4
$89.8M Buy
897,443
+53,412
+6% +$5.61M 0.03% 552
2018
Q3
$96.7M Sell
844,031
-239,928
-22% -$24.8M 0.03% 603
2018
Q2
$97.2M Sell
1,083,959
-831,329
-43% -$70.2M 0.03% 586
2018
Q1
$140M Sell
1,915,288
-202,417
-10% -$13.9M 0.04% 448
2017
Q4
$123M Sell
2,117,705
-641,752
-23% -$33.8M 0.04% 485
2017
Q3
$124M Sell
2,759,457
-28,665
-1% -$1.19M 0.04% 467
2017
Q2
$110M Buy
2,788,122
+238,294
+9% +$9.79M 0.04% 512
2017
Q1
$103M Buy
2,549,828
+217,836
+9% +$8.51M 0.03% 517
2016
Q4
$93.7M Sell
2,331,992
-17,641
-0.8% -$665K 0.03% 540
2016
Q3
$85.1M Sell
2,349,633
-317,751
-12% -$10.9M 0.03% 563
2016
Q2
$77.3M Buy
2,667,384
+620,571
+30% +$18.8M 0.03% 568
2016
Q1
$71.6M Sell
2,046,813
-238,146
-10% -$7.69M 0.03% 588
2015
Q4
$73.7M Sell
2,284,959
-151,425
-6% -$4.91M 0.03% 581
2015
Q3
$78.7M Buy
2,436,384
+83,889
+4% +$3.16M 0.03% 550
2015
Q2
$97.3M Buy
2,352,495
+1,181,502
+101% +$49.8M 0.04% 505
2015
Q1
$52.6M Buy
1,170,993
+59,955
+5% +$2.51M 0.02% 770
2014
Q4
$41.6M Buy
1,111,038
+407,837
+58% +$14.9M 0.02% 852
2014
Q3
$24.6M Buy
703,201
+68,056
+11% +$2.43M 0.01% 1133
2014
Q2
$22.4M Sell
635,145
-185
-0% -$6.18K 0.01% 1207
2014
Q1
$20.7M Sell
635,330
-292,256
-32% -$11.2M 0.01% 1239
2013
Q4
$39.1M Sell
927,586
-36,465
-4% -$1.5M 0.02% 872
2013
Q3
$38.4M Buy
964,051
+49,017
+5% +$2.06M 0.02% 826
2013
Q2
$37.8M Buy
+915,034
New +$37M 0.02% 771

Other funds holding HAE

Wells Fargo's HAE Position: Q1 2026 in Review

Wells Fargo reduced its Haemonetics (HAE) stake by 54% in Q1 2026, selling an estimated $3.18M and leaving 42,279 shares worth $2.38M. The position accounts for ﹤0.01% of the portfolio, ranked #3134.

Wells Fargo first reported a position in HAE in Q2 2013 and has held it in 52 quarters since. The position peaked at $144M in Q4 2020. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • Wells Fargo held 42,279 shares of Haemonetics worth $2.38M as of Q1 2026.
  • Wells Fargo sold 48,839 Haemonetics shares in Q1 2026, an estimated $3.18M.
  • Haemonetics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3134 holding.
  • Wells Fargo first reported a position in Haemonetics in Q2 2013 and has held it in 52 quarters since.
  • Wells Fargo's Haemonetics position peaked at $144M in Q4 2020.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.